Cruroplasty added to laparoscopic sleeve gastrectomy; does it decrease postoperative incidence of de-novo acid reflux?: A randomised controlled trial.
Cruroplasty
GERD
Gastrectomy
Reflux
Sleeve
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
16
04
2021
revised:
15
05
2021
accepted:
16
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
12
6
2021
Statut:
epublish
Résumé
Laparoscopic sleeve gastrectomy(LSG) is the most popular bariatric surgery worldwide. Postoperative de-novo acid reflux is one of the major common complications of the procedure. Different additive anti-reflux surgical techniques have been tried to decrease the complication although no favorable outcome is obtained. This study was conducted to evaluate effects of concurrent cruroplasty during LSG on postoperative de-novo acid reflux incidence rate. In current participant-blinded randomised controlled trial total of 80 subjects who were candidate for LSG were enrolled from the September 2018 to the December 2019. Following matching patients by gender and age, simple randomization method was held to allocate participants to LSG alone and LSG + cruroplasty groups with equal 40 members in each. Demographic data, length of hospital stay, and operation time was registered. Presence of acid reflux was looked by using gastroesophageal reflux disease-health related quality of life(GERD-HRQL) questionnaire prior and 6 months after surgery in follow-up visit. Finally 12/28 and 14/26 male/females with 38.5 ± 10.7 and 39.7 ± 8.2 years of age were recruited in LSG alone and LSG + cruroplasty, respectively.(p > 0.05) The length of operative time was significantly shorter in LSG alone(p < 0.01) although no obvious difference was existed in length of hospital stay between groups.(p = 0.7) Postoperative de-novo acid reflux also was not considerably lesser after cruroplasty compared with controls.(p = 0.1) The GERD-HRQL scores were not remarkable between subjects of study groups.(p > 0.05). Equipping LSG with concurrent cruroplasty to diminish postoperative de-novo gastroesophageal acid reflux is not effective and not recommended in absence of other indications.
Sections du résumé
BACKGROUND
BACKGROUND
Laparoscopic sleeve gastrectomy(LSG) is the most popular bariatric surgery worldwide. Postoperative de-novo acid reflux is one of the major common complications of the procedure. Different additive anti-reflux surgical techniques have been tried to decrease the complication although no favorable outcome is obtained. This study was conducted to evaluate effects of concurrent cruroplasty during LSG on postoperative de-novo acid reflux incidence rate.
METHODS
METHODS
In current participant-blinded randomised controlled trial total of 80 subjects who were candidate for LSG were enrolled from the September 2018 to the December 2019. Following matching patients by gender and age, simple randomization method was held to allocate participants to LSG alone and LSG + cruroplasty groups with equal 40 members in each. Demographic data, length of hospital stay, and operation time was registered. Presence of acid reflux was looked by using gastroesophageal reflux disease-health related quality of life(GERD-HRQL) questionnaire prior and 6 months after surgery in follow-up visit.
RESULTS
RESULTS
Finally 12/28 and 14/26 male/females with 38.5 ± 10.7 and 39.7 ± 8.2 years of age were recruited in LSG alone and LSG + cruroplasty, respectively.(p > 0.05) The length of operative time was significantly shorter in LSG alone(p < 0.01) although no obvious difference was existed in length of hospital stay between groups.(p = 0.7) Postoperative de-novo acid reflux also was not considerably lesser after cruroplasty compared with controls.(p = 0.1) The GERD-HRQL scores were not remarkable between subjects of study groups.(p > 0.05).
CONCLUSION
CONCLUSIONS
Equipping LSG with concurrent cruroplasty to diminish postoperative de-novo gastroesophageal acid reflux is not effective and not recommended in absence of other indications.
Identifiants
pubmed: 34113443
doi: 10.1016/j.amsu.2021.102415
pii: S2049-0801(21)00365-4
pmc: PMC8170119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102415Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declared that they have no competing interests.
Références
Gastroenterol Res Pract. 2017;2017:6565403
pubmed: 29259626
Obes Surg. 2016 Jan;26(1):61-6
pubmed: 25990380
Obes Surg. 2012 Dec;22(12):1874-9
pubmed: 22915063
Am J Surg. 2016 Jan;211(1):250-67
pubmed: 26341463
Obes Surg. 2015 Dec;25(12):2430-5
pubmed: 26428250
Obes Surg. 2017 Jan;27(1):59-63
pubmed: 27178407
Surg Obes Relat Dis. 2011 Nov-Dec;7(6):709-13
pubmed: 21955743
JAMA. 2012 Feb 1;307(5):491-7
pubmed: 22253363
Obes Surg. 2015 Sep;25(9):1703-10
pubmed: 25676156
Ann Surg. 1996 Jun;223(6):673-85; discussion 685-7
pubmed: 8645041
Obes Surg. 2015 Jan;25(1):159-66
pubmed: 25348434
Surg Endosc. 2016 Jun;30(6):2374-81
pubmed: 26428202
PLoS Med. 2010 Mar 24;7(3):e1000251
pubmed: 20352064
Surg Endosc. 2020 Jan;34(1):396-407
pubmed: 30993513
Dis Esophagus. 2007;20(2):130-4
pubmed: 17439596
Am J Surg. 2016 Jan;211(1):226-38
pubmed: 26520872
JAMA Surg. 2017 Feb 1;152(2):136-141
pubmed: 27784062